Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-04

AUTHORS

Thomas E. Hutson, Svetislava Vukelja, Daniel Atienza, Sanjay Awasthi, Robert Delaune, Margaret Deutsch, Philip Y. Dien, Thomas F. Gregory, Michael J. Kolodziej, Joseph J. Muscato, Robert N. Raju, Robert L. Ruxer, Stephanie Mull, Des Ilegbodu, Karen Hood, Steven Nicol, William Berry

ABSTRACT

OBJECTIVES: Gemcitabine (G) plus cisplatin (C) is standard care for metastatic transitional cell carcinoma (TCC) of the urothelium. Pemetrexed (P), alone or in combination with G, is active in metastatic TCC. However, the safety and efficacy of P combined with GC therapy is unknown. This phase I trial was designed to determine the maximum tolerated dose (MTD) of GC followed by P+G in patients with metastatic TCC. METHODS: Cohorts of 3 to 6 patients received escalating doses 28-day cycles (maximum 6 cycles): G 800-1,000 mg/m2 on days 1 and 15; P 400-500 mg/m2 on day 15; and C 50-70 mg/m2 on day 1. All patients received folic acid, vitamin B12, and full supportive care. The 3+3 standard phase I escalation rule was used to determine MTD. RESULTS: Fifteen patients registered: 13/15 white males; median age 70 years (range, 53-82); 11/15 had KPS>or=90. At dose level 0, 2/4 patients experienced unrelated DLTs, and 1 patient was replaced (completed<1 cycle). Dose escalation proceeded to dose level 1. At level 1, 4/6 patients experienced DLTs; dosing decreased to level 0 and 4/5 patients experienced DLTs. The MTD was not determined. The 2 patients that completed 6 cycles both had partial responses. Grades 3-4 hematologic toxicities included neutropenia (60%), leukopenia (20%), and febrile neutropenia (13%). CONCLUSION: Adding P to the standard GC regimen as first-line therapy for metastatic TCC produced no benefit. The MTD exceeded therapeutic gemcitabine and cisplatin doses for urothelial cancer and thus the study was aborted. More... »

PAGES

151-158

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-007-9111-2

DOI

http://dx.doi.org/10.1007/s10637-007-9111-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037264341

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18236006


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Transitional Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Folic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glutamates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Guanine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematologic Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pemetrexed", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urinary Bladder Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urothelium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vitamin B 12", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vitamin B Complex", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Texas Oncology", 
          "id": "https://www.grid.ac/institutes/grid.477898.d", 
          "name": [
            "US Oncology Research, Inc., Genitourinary Oncology Program, Houston, TX, USA", 
            "Baylor-Sammons Cancer Center, 3535 Worth Street, Suite 185, 75246, Dallas, TX, USA", 
            "Texas Oncology, P.A., Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hutson", 
        "givenName": "Thomas E.", 
        "id": "sg:person.0626761272.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626761272.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "Tyler Cancer Center and Texas Oncology, P.A., Tyler, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vukelja", 
        "givenName": "Svetislava", 
        "id": "sg:person.01113127513.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113127513.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Virginia Oncology Associates", 
          "id": "https://www.grid.ac/institutes/grid.478132.b", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "Virginia Oncology Associates-Lake Wright, Norfolk, VA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Atienza", 
        "givenName": "Daniel", 
        "id": "sg:person.0605145415.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605145415.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "Texas Cancer Center-Arlington South and Texas Oncology, P.A., Arlington, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Awasthi", 
        "givenName": "Sanjay", 
        "id": "sg:person.01121374046.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121374046.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "Minnesota Oncology Hematology, Mapplewood, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Delaune", 
        "givenName": "Robert", 
        "id": "sg:person.01275471313.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275471313.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "Tyler Cancer Center and Texas Oncology, P.A., Tyler, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Deutsch", 
        "givenName": "Margaret", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Minnesota Oncology", 
          "id": "https://www.grid.ac/institutes/grid.492844.7", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "Minnesota Oncology Hematology, Burnsville, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dien", 
        "givenName": "Philip Y.", 
        "id": "sg:person.0620200413.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620200413.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "Tyler Cancer Center and Texas Oncology, P.A., Tyler, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gregory", 
        "givenName": "Thomas F.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "New York Oncology Hematology-Albany Regional Cancer Center, Albany, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kolodziej", 
        "givenName": "Michael J.", 
        "id": "sg:person.01055776274.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055776274.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "Missouri Center Associates, Columbia, MO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Muscato", 
        "givenName": "Joseph J.", 
        "id": "sg:person.01002542213.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002542213.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "Dayton Oncology and Hematology-Kettering, Kettering, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raju", 
        "givenName": "Robert N.", 
        "id": "sg:person.01320012243.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320012243.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Texas Oncology", 
          "id": "https://www.grid.ac/institutes/grid.477898.d", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "Texas Oncology, P.A., Fort Worth, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruxer", 
        "givenName": "Robert L.", 
        "id": "sg:person.01116770613.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116770613.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mull", 
        "givenName": "Stephanie", 
        "id": "sg:person.0601256155.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601256155.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Oncology Network", 
          "id": "https://www.grid.ac/institutes/grid.420754.0", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ilegbodu", 
        "givenName": "Des", 
        "id": "sg:person.01355346777.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355346777.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hood", 
        "givenName": "Karen", 
        "id": "sg:person.01301332413.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301332413.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nicol", 
        "givenName": "Steven", 
        "id": "sg:person.01055106401.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055106401.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rex Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415902.b", 
          "name": [
            "US Oncology Research, Inc., Houston, TX, USA", 
            "Raleigh Hematology-Oncology Associates, P.A., Raleigh, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berry", 
        "givenName": "William", 
        "id": "sg:person.0623476543.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623476543.98"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-04-0218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004413180"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.07.7016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006266374"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdl286", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007486164"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.6699", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009913379"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(20010801)92:3<595::aid-cncr1359>3.0.co;2-d", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022873469"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-006-9020-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026239180", 
          "https://doi.org/10.1007/s10637-006-9020-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-006-9020-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026239180", 
          "https://doi.org/10.1007/s10637-006-9020-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.07.757", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028324313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.07.757", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028324313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdf017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049401584"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000180580", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051087304"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008336931378", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056303259"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.11.136", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203976"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074507216", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.8.1748", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074622904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.18.3247", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074698111"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.17.3068", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074702294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083060235", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-04", 
    "datePublishedReg": "2008-04-01", 
    "description": "OBJECTIVES: Gemcitabine (G) plus cisplatin (C) is standard care for metastatic transitional cell carcinoma (TCC) of the urothelium. Pemetrexed (P), alone or in combination with G, is active in metastatic TCC. However, the safety and efficacy of P combined with GC therapy is unknown. This phase I trial was designed to determine the maximum tolerated dose (MTD) of GC followed by P+G in patients with metastatic TCC.\nMETHODS: Cohorts of 3 to 6 patients received escalating doses 28-day cycles (maximum 6 cycles): G 800-1,000 mg/m2 on days 1 and 15; P 400-500 mg/m2 on day 15; and C 50-70 mg/m2 on day 1. All patients received folic acid, vitamin B12, and full supportive care. The 3+3 standard phase I escalation rule was used to determine MTD.\nRESULTS: Fifteen patients registered: 13/15 white males; median age 70 years (range, 53-82); 11/15 had KPS>or=90. At dose level 0, 2/4 patients experienced unrelated DLTs, and 1 patient was replaced (completed<1 cycle). Dose escalation proceeded to dose level 1. At level 1, 4/6 patients experienced DLTs; dosing decreased to level 0 and 4/5 patients experienced DLTs. The MTD was not determined. The 2 patients that completed 6 cycles both had partial responses. Grades 3-4 hematologic toxicities included neutropenia (60%), leukopenia (20%), and febrile neutropenia (13%).\nCONCLUSION: Adding P to the standard GC regimen as first-line therapy for metastatic TCC produced no benefit. The MTD exceeded therapeutic gemcitabine and cisplatin doses for urothelial cancer and thus the study was aborted.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-007-9111-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "26"
      }
    ], 
    "name": "Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium", 
    "pagination": "151-158", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-007-9111-2"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b183b1a084087b3a7c316d0f156353662d7e94c891cd7bb126e526613708ecf2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037264341"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18236006"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-007-9111-2", 
      "https://app.dimensions.ai/details/publication/pub.1037264341"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000376_0000000376/records_56171_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10637-007-9111-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-007-9111-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-007-9111-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-007-9111-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-007-9111-2'


 

This table displays all metadata directly associated to this object as RDF triples.

349 TRIPLES      21 PREDICATES      69 URIs      44 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-007-9111-2 schema:about N072bc7dd0c8644c29f271ebfec14d462
2 N08eba409e0a94ccfa47d348fc4a5b0a6
3 N0b0e39e4d35b4aa59164ceda2bb02462
4 N194c939e3e0c43918ffd394cc9605c2d
5 N196433c3d81d46e49d073e45ff4661a5
6 N263f58d61684406382101bf6fb2d5f4f
7 N33dd0af0769c4a7782de1c6746237ae8
8 N41c19b1ac3ad47f0a2e3fdfaba920972
9 N6bfde4c5ad55491aa323a3509709ee0f
10 N7437f3df48654b61a2a805db6a77df83
11 N8a9727e07f454542872a90881958b6a3
12 N90e970e60ada4020ae94d077015bbf38
13 Na447f04e61d54c3bb2f1843218333e52
14 Nae018bef38fd4aae9ead7c077a2b3d83
15 Naf0764608d0f4089bcd59db8773c5839
16 Nb43549b56d604a2f871768492d52a7ba
17 Nbc5d74edc24645fdad3f071caa6155db
18 Nd1cd68c588be400497ea16d8835bbb8d
19 Nddd96716b227400790061fee229fee1b
20 Ne04e510388044bc8ace7c478101dc327
21 Ne5287fada5b44a95aafb90cb07aaf1f6
22 Nf529c81834764ccf84458b9d92c1c94e
23 Nf84ee9facebe40d5a0dad360f3af5885
24 anzsrc-for:11
25 anzsrc-for:1103
26 schema:author N2a80405b877d4bc28bdb23821742b4b9
27 schema:citation sg:pub.10.1007/s10637-006-9020-9
28 https://app.dimensions.ai/details/publication/pub.1074507216
29 https://app.dimensions.ai/details/publication/pub.1083060235
30 https://doi.org/10.1002/1097-0142(20010801)92:3<595::aid-cncr1359>3.0.co;2-d
31 https://doi.org/10.1023/a:1008336931378
32 https://doi.org/10.1093/annonc/mdf017
33 https://doi.org/10.1093/annonc/mdl286
34 https://doi.org/10.1093/jnci/92.3.205
35 https://doi.org/10.1158/1078-0432.ccr-04-0218
36 https://doi.org/10.1159/000180580
37 https://doi.org/10.1200/jco.2000.18.17.3068
38 https://doi.org/10.1200/jco.2000.18.18.3247
39 https://doi.org/10.1200/jco.2000.18.8.1748
40 https://doi.org/10.1200/jco.2003.11.136
41 https://doi.org/10.1200/jco.2005.03.6699
42 https://doi.org/10.1200/jco.2005.07.757
43 https://doi.org/10.1200/jco.2006.07.7016
44 schema:datePublished 2008-04
45 schema:datePublishedReg 2008-04-01
46 schema:description OBJECTIVES: Gemcitabine (G) plus cisplatin (C) is standard care for metastatic transitional cell carcinoma (TCC) of the urothelium. Pemetrexed (P), alone or in combination with G, is active in metastatic TCC. However, the safety and efficacy of P combined with GC therapy is unknown. This phase I trial was designed to determine the maximum tolerated dose (MTD) of GC followed by P+G in patients with metastatic TCC. METHODS: Cohorts of 3 to 6 patients received escalating doses 28-day cycles (maximum 6 cycles): G 800-1,000 mg/m2 on days 1 and 15; P 400-500 mg/m2 on day 15; and C 50-70 mg/m2 on day 1. All patients received folic acid, vitamin B12, and full supportive care. The 3+3 standard phase I escalation rule was used to determine MTD. RESULTS: Fifteen patients registered: 13/15 white males; median age 70 years (range, 53-82); 11/15 had KPS>or=90. At dose level 0, 2/4 patients experienced unrelated DLTs, and 1 patient was replaced (completed<1 cycle). Dose escalation proceeded to dose level 1. At level 1, 4/6 patients experienced DLTs; dosing decreased to level 0 and 4/5 patients experienced DLTs. The MTD was not determined. The 2 patients that completed 6 cycles both had partial responses. Grades 3-4 hematologic toxicities included neutropenia (60%), leukopenia (20%), and febrile neutropenia (13%). CONCLUSION: Adding P to the standard GC regimen as first-line therapy for metastatic TCC produced no benefit. The MTD exceeded therapeutic gemcitabine and cisplatin doses for urothelial cancer and thus the study was aborted.
47 schema:genre research_article
48 schema:inLanguage en
49 schema:isAccessibleForFree false
50 schema:isPartOf N85f82992ab59456c85f7b140cab2fb1a
51 Ncade5e186aff483eaa913b91766f8257
52 sg:journal.1094201
53 schema:name Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium
54 schema:pagination 151-158
55 schema:productId N026c83f93e164d2a84598923802410a4
56 N3896d0d9e08544fb84fc8081466d6ac7
57 N70fd3af71e9b422083e244a84b5cd947
58 Ndf105f1d1deb40b8bafd45281da6a4bb
59 Ne6fce64a291844f284616673ddd71046
60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037264341
61 https://doi.org/10.1007/s10637-007-9111-2
62 schema:sdDatePublished 2019-04-15T09:16
63 schema:sdLicense https://scigraph.springernature.com/explorer/license/
64 schema:sdPublisher N215d894d9d7247b086ac0c979e5a879d
65 schema:url http://link.springer.com/10.1007%2Fs10637-007-9111-2
66 sgo:license sg:explorer/license/
67 sgo:sdDataset articles
68 rdf:type schema:ScholarlyArticle
69 N026c83f93e164d2a84598923802410a4 schema:name doi
70 schema:value 10.1007/s10637-007-9111-2
71 rdf:type schema:PropertyValue
72 N02fea0916f2b4c48b197d3030705bc9c rdf:first sg:person.01301332413.03
73 rdf:rest Nfcd3dd4b98434f768749290c1cb67688
74 N072bc7dd0c8644c29f271ebfec14d462 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Aged, 80 and over
76 rdf:type schema:DefinedTerm
77 N08eba409e0a94ccfa47d348fc4a5b0a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Male
79 rdf:type schema:DefinedTerm
80 N0b0e39e4d35b4aa59164ceda2bb02462 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Treatment Outcome
82 rdf:type schema:DefinedTerm
83 N194c939e3e0c43918ffd394cc9605c2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Urothelium
85 rdf:type schema:DefinedTerm
86 N196433c3d81d46e49d073e45ff4661a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Carcinoma, Transitional Cell
88 rdf:type schema:DefinedTerm
89 N215d894d9d7247b086ac0c979e5a879d schema:name Springer Nature - SN SciGraph project
90 rdf:type schema:Organization
91 N263f58d61684406382101bf6fb2d5f4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Urinary Bladder Neoplasms
93 rdf:type schema:DefinedTerm
94 N2a80405b877d4bc28bdb23821742b4b9 rdf:first sg:person.0626761272.86
95 rdf:rest Nc1904aed9abf4936aaa881eec97653c9
96 N31d980360c994fe8bb47a4a10dcd178e rdf:first sg:person.01275471313.33
97 rdf:rest N5295d7acc76546d9806d1796fe149ba1
98 N32d9cc87855b4e2788a5404719b46056 rdf:first sg:person.0605145415.37
99 rdf:rest Nba20c86f47fd4841acb31597b84476ab
100 N33dd0af0769c4a7782de1c6746237ae8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Maximum Tolerated Dose
102 rdf:type schema:DefinedTerm
103 N3896d0d9e08544fb84fc8081466d6ac7 schema:name dimensions_id
104 schema:value pub.1037264341
105 rdf:type schema:PropertyValue
106 N41c19b1ac3ad47f0a2e3fdfaba920972 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Cisplatin
108 rdf:type schema:DefinedTerm
109 N5295d7acc76546d9806d1796fe149ba1 rdf:first N71a84a7a7ca445dbab05c183f52da163
110 rdf:rest N89d6574ae32c444da5d27cc319c25ac5
111 N6bfde4c5ad55491aa323a3509709ee0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Female
113 rdf:type schema:DefinedTerm
114 N6c5284af4c934ae6ab0a2647ea30cca9 rdf:first Neb44fb10e6d24299830e29d450c0e73b
115 rdf:rest Ncf43126239684b29b6aa52dd45629288
116 N70fd3af71e9b422083e244a84b5cd947 schema:name pubmed_id
117 schema:value 18236006
118 rdf:type schema:PropertyValue
119 N71a84a7a7ca445dbab05c183f52da163 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
120 schema:familyName Deutsch
121 schema:givenName Margaret
122 rdf:type schema:Person
123 N7437f3df48654b61a2a805db6a77df83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Hematologic Diseases
125 rdf:type schema:DefinedTerm
126 N7a6d950f95564357a7ccc0938024b5f4 rdf:first sg:person.01320012243.89
127 rdf:rest Ndad14a3be072400ebf46fa3144fbcb05
128 N7ed4bab5eb1a4d04aa50869677ae2066 rdf:first sg:person.0623476543.98
129 rdf:rest rdf:nil
130 N85f82992ab59456c85f7b140cab2fb1a schema:volumeNumber 26
131 rdf:type schema:PublicationVolume
132 N89d6574ae32c444da5d27cc319c25ac5 rdf:first sg:person.0620200413.43
133 rdf:rest N6c5284af4c934ae6ab0a2647ea30cca9
134 N8a9727e07f454542872a90881958b6a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Vitamin B Complex
136 rdf:type schema:DefinedTerm
137 N8de12a5154d648c6a0874fd6d778e39e rdf:first sg:person.01002542213.40
138 rdf:rest N7a6d950f95564357a7ccc0938024b5f4
139 N90e970e60ada4020ae94d077015bbf38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Vitamin B 12
141 rdf:type schema:DefinedTerm
142 Na1a0a0054eb34ab0a8435a32d84f9a08 rdf:first sg:person.0601256155.73
143 rdf:rest Na2b630827c464da6a5c77c6dd87351fe
144 Na2b630827c464da6a5c77c6dd87351fe rdf:first sg:person.01355346777.33
145 rdf:rest N02fea0916f2b4c48b197d3030705bc9c
146 Na447f04e61d54c3bb2f1843218333e52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Folic Acid
148 rdf:type schema:DefinedTerm
149 Nae018bef38fd4aae9ead7c077a2b3d83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Neoplasm Metastasis
151 rdf:type schema:DefinedTerm
152 Naf0764608d0f4089bcd59db8773c5839 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Antineoplastic Combined Chemotherapy Protocols
154 rdf:type schema:DefinedTerm
155 Nb43549b56d604a2f871768492d52a7ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Deoxycytidine
157 rdf:type schema:DefinedTerm
158 Nba20c86f47fd4841acb31597b84476ab rdf:first sg:person.01121374046.60
159 rdf:rest N31d980360c994fe8bb47a4a10dcd178e
160 Nbc5d74edc24645fdad3f071caa6155db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Glutamates
162 rdf:type schema:DefinedTerm
163 Nc1904aed9abf4936aaa881eec97653c9 rdf:first sg:person.01113127513.84
164 rdf:rest N32d9cc87855b4e2788a5404719b46056
165 Ncade5e186aff483eaa913b91766f8257 schema:issueNumber 2
166 rdf:type schema:PublicationIssue
167 Ncf43126239684b29b6aa52dd45629288 rdf:first sg:person.01055776274.47
168 rdf:rest N8de12a5154d648c6a0874fd6d778e39e
169 Nd1cd68c588be400497ea16d8835bbb8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Middle Aged
171 rdf:type schema:DefinedTerm
172 Ndad14a3be072400ebf46fa3144fbcb05 rdf:first sg:person.01116770613.85
173 rdf:rest Na1a0a0054eb34ab0a8435a32d84f9a08
174 Nddd96716b227400790061fee229fee1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Guanine
176 rdf:type schema:DefinedTerm
177 Ndf105f1d1deb40b8bafd45281da6a4bb schema:name readcube_id
178 schema:value b183b1a084087b3a7c316d0f156353662d7e94c891cd7bb126e526613708ecf2
179 rdf:type schema:PropertyValue
180 Ne04e510388044bc8ace7c478101dc327 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Pemetrexed
182 rdf:type schema:DefinedTerm
183 Ne5287fada5b44a95aafb90cb07aaf1f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Dose-Response Relationship, Drug
185 rdf:type schema:DefinedTerm
186 Ne6fce64a291844f284616673ddd71046 schema:name nlm_unique_id
187 schema:value 8309330
188 rdf:type schema:PropertyValue
189 Neb44fb10e6d24299830e29d450c0e73b schema:affiliation https://www.grid.ac/institutes/grid.420754.0
190 schema:familyName Gregory
191 schema:givenName Thomas F.
192 rdf:type schema:Person
193 Nf529c81834764ccf84458b9d92c1c94e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Aged
195 rdf:type schema:DefinedTerm
196 Nf84ee9facebe40d5a0dad360f3af5885 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Humans
198 rdf:type schema:DefinedTerm
199 Nfcd3dd4b98434f768749290c1cb67688 rdf:first sg:person.01055106401.73
200 rdf:rest N7ed4bab5eb1a4d04aa50869677ae2066
201 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
202 schema:name Medical and Health Sciences
203 rdf:type schema:DefinedTerm
204 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
205 schema:name Clinical Sciences
206 rdf:type schema:DefinedTerm
207 sg:journal.1094201 schema:issn 0167-6997
208 1573-0646
209 schema:name Investigational New Drugs
210 rdf:type schema:Periodical
211 sg:person.01002542213.40 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
212 schema:familyName Muscato
213 schema:givenName Joseph J.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002542213.40
215 rdf:type schema:Person
216 sg:person.01055106401.73 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
217 schema:familyName Nicol
218 schema:givenName Steven
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055106401.73
220 rdf:type schema:Person
221 sg:person.01055776274.47 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
222 schema:familyName Kolodziej
223 schema:givenName Michael J.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055776274.47
225 rdf:type schema:Person
226 sg:person.01113127513.84 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
227 schema:familyName Vukelja
228 schema:givenName Svetislava
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113127513.84
230 rdf:type schema:Person
231 sg:person.01116770613.85 schema:affiliation https://www.grid.ac/institutes/grid.477898.d
232 schema:familyName Ruxer
233 schema:givenName Robert L.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116770613.85
235 rdf:type schema:Person
236 sg:person.01121374046.60 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
237 schema:familyName Awasthi
238 schema:givenName Sanjay
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121374046.60
240 rdf:type schema:Person
241 sg:person.01275471313.33 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
242 schema:familyName Delaune
243 schema:givenName Robert
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275471313.33
245 rdf:type schema:Person
246 sg:person.01301332413.03 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
247 schema:familyName Hood
248 schema:givenName Karen
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301332413.03
250 rdf:type schema:Person
251 sg:person.01320012243.89 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
252 schema:familyName Raju
253 schema:givenName Robert N.
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320012243.89
255 rdf:type schema:Person
256 sg:person.01355346777.33 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
257 schema:familyName Ilegbodu
258 schema:givenName Des
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355346777.33
260 rdf:type schema:Person
261 sg:person.0601256155.73 schema:affiliation https://www.grid.ac/institutes/grid.420754.0
262 schema:familyName Mull
263 schema:givenName Stephanie
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601256155.73
265 rdf:type schema:Person
266 sg:person.0605145415.37 schema:affiliation https://www.grid.ac/institutes/grid.478132.b
267 schema:familyName Atienza
268 schema:givenName Daniel
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605145415.37
270 rdf:type schema:Person
271 sg:person.0620200413.43 schema:affiliation https://www.grid.ac/institutes/grid.492844.7
272 schema:familyName Dien
273 schema:givenName Philip Y.
274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620200413.43
275 rdf:type schema:Person
276 sg:person.0623476543.98 schema:affiliation https://www.grid.ac/institutes/grid.415902.b
277 schema:familyName Berry
278 schema:givenName William
279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623476543.98
280 rdf:type schema:Person
281 sg:person.0626761272.86 schema:affiliation https://www.grid.ac/institutes/grid.477898.d
282 schema:familyName Hutson
283 schema:givenName Thomas E.
284 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626761272.86
285 rdf:type schema:Person
286 sg:pub.10.1007/s10637-006-9020-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026239180
287 https://doi.org/10.1007/s10637-006-9020-9
288 rdf:type schema:CreativeWork
289 https://app.dimensions.ai/details/publication/pub.1074507216 schema:CreativeWork
290 https://app.dimensions.ai/details/publication/pub.1083060235 schema:CreativeWork
291 https://doi.org/10.1002/1097-0142(20010801)92:3<595::aid-cncr1359>3.0.co;2-d schema:sameAs https://app.dimensions.ai/details/publication/pub.1022873469
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1023/a:1008336931378 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056303259
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1093/annonc/mdf017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049401584
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1093/annonc/mdl286 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007486164
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1158/1078-0432.ccr-04-0218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004413180
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1159/000180580 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051087304
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1200/jco.2000.18.17.3068 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074702294
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1200/jco.2000.18.18.3247 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074698111
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1200/jco.2000.18.8.1748 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074622904
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1200/jco.2003.11.136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203976
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1200/jco.2005.03.6699 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009913379
314 rdf:type schema:CreativeWork
315 https://doi.org/10.1200/jco.2005.07.757 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028324313
316 rdf:type schema:CreativeWork
317 https://doi.org/10.1200/jco.2006.07.7016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006266374
318 rdf:type schema:CreativeWork
319 https://www.grid.ac/institutes/grid.415902.b schema:alternateName Rex Hospital
320 schema:name Raleigh Hematology-Oncology Associates, P.A., Raleigh, NC, USA
321 US Oncology Research, Inc., Houston, TX, USA
322 rdf:type schema:Organization
323 https://www.grid.ac/institutes/grid.417540.3 schema:alternateName Eli Lilly (United States)
324 schema:name Eli Lilly and Company, Indianapolis, IN, USA
325 rdf:type schema:Organization
326 https://www.grid.ac/institutes/grid.420754.0 schema:alternateName US Oncology Network
327 schema:name Dayton Oncology and Hematology-Kettering, Kettering, OH, USA
328 Minnesota Oncology Hematology, Mapplewood, MN, USA
329 Missouri Center Associates, Columbia, MO, USA
330 New York Oncology Hematology-Albany Regional Cancer Center, Albany, NY, USA
331 Texas Cancer Center-Arlington South and Texas Oncology, P.A., Arlington, TX, USA
332 Tyler Cancer Center and Texas Oncology, P.A., Tyler, TX, USA
333 US Oncology Research, Inc., Houston, TX, USA
334 rdf:type schema:Organization
335 https://www.grid.ac/institutes/grid.477898.d schema:alternateName Texas Oncology
336 schema:name Baylor-Sammons Cancer Center, 3535 Worth Street, Suite 185, 75246, Dallas, TX, USA
337 Texas Oncology, P.A., Dallas, TX, USA
338 Texas Oncology, P.A., Fort Worth, TX, USA
339 US Oncology Research, Inc., Genitourinary Oncology Program, Houston, TX, USA
340 US Oncology Research, Inc., Houston, TX, USA
341 rdf:type schema:Organization
342 https://www.grid.ac/institutes/grid.478132.b schema:alternateName Virginia Oncology Associates
343 schema:name US Oncology Research, Inc., Houston, TX, USA
344 Virginia Oncology Associates-Lake Wright, Norfolk, VA, USA
345 rdf:type schema:Organization
346 https://www.grid.ac/institutes/grid.492844.7 schema:alternateName Minnesota Oncology
347 schema:name Minnesota Oncology Hematology, Burnsville, MN, USA
348 US Oncology Research, Inc., Houston, TX, USA
349 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...